

PRODUCT INFORMATION



A-922500

Item No. 10012708

CAS Registry No.: 959122-11-3

Formal Name: 2R-[[4'-[[[(phenylamino)carbonyl]amino][1R,1'-biphenyl]-4-yl-carbonyl]-cyclopentanecarboxylic acid

Synonym: (1R,2R)-2-(4'-(3-phenylureido)biphenylcarbonyl)-cyclopentanecarboxylic acid

MF: C₂₆H₂₄N₂O₄


FW: 428.5

Purity: ≥95%

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

A-922500 is supplied as a crystalline solid. A stock solution may be made by dissolving the A-922500 in the solvent of choice, which should be purged with an inert gas. A-922500 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of A-922500 in ethanol is approximately 0.2 mg/ml and approximately 20 mg/ml in DMSO and DMF.

A-922500 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, A-922500 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. A-922500 has a solubility of approximately 0.1 mg/ml in a 1:10 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Diacylglycerol acyltransferases (DGATs) catalyze the final step in triglyceride synthesis. DGAT-1 deficient mice demonstrate a phenotype that is protective against the development of diet-induced obesity (DIO) or insulin resistance, implicating the actions of this enzyme in the development of such metabolic disorders. A-922500 is a potent orally active inhibitor of DGAT-1 activity, inhibiting both human and mouse forms of the enzymes with IC₅₀ values of 7 and 24 nM, respectively.¹ When administered at 3 mg/kg to DIO mice, A-922500 conferred significant weight loss within seven days without affecting food intake and significantly reduced plasma and liver triglycerides with chronic dosing.¹ A-922500 does not inhibit DGAT-2, ACAT-1, or ACAT-2.¹

Reference

1. Zhao, G., Souers, A.J., Voorbach, M., *et al.* Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. *J. Med. Chem.* **51**, 380-383 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/15/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM